RemeGen is a leading biotech innovator in China. The company believes biologics are the future of medicine, and it is ready to take therapeutic innovations to the global stage. The company is aligning its investments in scientific research, manufacturing and commercialization to change the way cancer, autoimmune and eye diseases are treated. RemeGen conducts rigorous research and development in areas of serious unmet medical need, with a focus on antibody and fusion proteins, antibody-drug conjugates (ADCs), and bifunctional antibodies, to target treatments and attack disease. The potential of these therapies can be seen in the company’s rich pipeline of innovative drugs with over 15 indications, with five of those indications currently in pivotal trials.